PATENT

DOCKET NO: TJU0001-107

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application of: Scott A. Waldman et al..

Serial No.: 10/621,684

Group Art Unit: 1639

Filing Date: July 17, 2003

Examiner: Sue Xu Liu

For: ST RECEPTOR BINDING COMPOUNDS AND METHODS OF USING THE

SAME

EXPRESS MAIL LABEL NO: EV 882774355 US DATE OF DEPOSIT: September 28, 2006

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

## SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Pursuant to 37 C.F.R. §§ 1.56 and in accordance with 37 C.F.R. §§ 1.97 and 1.98, information relating to the above-identified application is hereby disclosed, the Examiner in charge of the above-identified application is requested to consider and make of record the reference listed on the PTO Form SB/08B, formerly known as PTO Form 1449 submitted herewith.

Inclusion of the information submitted herewith is not to be construed as an admission that the information is material as that term is defined in 37 C.F.R. § 1.56(b),

In accordance with 37 C.F.R. § 1.97(g), the filing of this Supplemental Information Disclosure Statement shall not be construed to mean that a search has been made.

## This Supplemental Information Disclosure Statement is being filed:

within three months of the filing date of the patent application.		
within three months of the date of entry into the national stage as set forth in 37 C.F.R. $\S$ 1.491 of the international application.		
before the mailing date of a first Office Action on the merits.		
before the mailing date of a first Office Action on the merits after the filing of a Request for Continued Examination under 8 1.114.		

Δ	of a Request for Continued Examination under § 1.114, but before the mai date of a Final Office Action under 37 C.F.R. § 1.116 or a Notice Allowance under 37 C.F.R. § 1.311, and accordingly is accompanied by:				
	$\boxtimes$	the Statement under 37 C.F.R. § 1.97(e) (see "Statement" below);			
		or			
		the Fee of \$180.00 set forth in 37 C.F.R. § 1.17(p); or			
		No fee is owed by the applicant(s).			
	In accordance with 37 C.F.R. $\S$ 1.129(a), this Information Disclosure Statement is being filed in connection with the $\square$ first or $\square$ second After Final Submission, and accordingly is accompanied by the Statement under 37 C.F.R. $\S$ 1.97(e) (see "Statement" below) and the fee of \$180.00 as set forth in 37 C.F.R. $\S$ 1.17(p), is attached.				
	after the mailing date of a Final Office Action under 37 C.F.R. § 1.116 or a Notice of Allowance under 37 C.F.R. § 1.311, but before, or simultaneously with, the payment of the Issue Fee, and accordingly is accompanied by the Statement under 37 C.F.R. § 1.97(e), and the Fee of \$180.00 set forth in 37 C.F.R. § 1.17(p).				
$\boxtimes$	A copy of the reference listed on the attached PTO Form SB/08B, formerly known as PTO Form 1449, is enclosed.				
EXCEPT THAT:					
		In view of the voluminous nature of references, and the likelihood that these reference are available to the Examiner, copies are not enclosed herewith.			
		In accordance with 37 C.F.R. § 1.98(d), copies of the following references listed on the attached PTO Form SB/08A and PTO Form SB/08B, formerly known as PTO Form 1449 are not enclosed herewith because they were previously cited by or submitted to the U.S. Patent and Trademark Office in patent application(s) @@ for which a claim for priority under 35 U.S.C. § 120 have been made in the instant application.			
		If any of the foregoing publications are not available to the Examiner, Applicant will endeavor to supply copies at the Examiner's request.			

Statement under 37 C.F.R. § 1.97(e)

	* ','		
$\boxtimes$	The undersigned attorney hereby states that each item information containe in the Information Disclosure Statement was cited in a communication from foreign patent office in a counterpart foreign patent application not more that three months prior to the filing of the Information Disclosure Statement.		
Stater	nent under 37 C.F.R. § 1.704(d)		
Fees	The undersigned attorney hereby states that each item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart application and the communication was not received by any individual designated in §1.56(c) more than 30 days prior to the filing of the Information Disclosure Statement.		
$\boxtimes$	No Fee is owed by the applicant(s).		
	The Supplemental Information Disclosure Statement Fee of \$180.00 unde C.F.R. § 1.17(p) is enclosed herewith.		
	The Petition Fee of \$130.00 under 37 C.F.R. § 1.17(i)(1) is enclosed herewith.		
Metho	od of Payment of Fees		

submitted in duplicate.

Charge Deposit Account No. 50-1275 in the amount of \$180.00. This form is submitted in duplicate.

Attached is a check in the amount of \$ . This form is

Please charge any deficiency or credit any overpayment to Deposit Account 50-1275.

No fee or Statement is required under 37 C.F.R. § 1.97(b).

Respectfully submitted,

Dated: September 28, 2006

COZEN O'CONNOR, P.C. 1900 Market Street, 4<sup>th</sup> Floor Philadelphia, PA 19103-3508 (215) 665-2000 - Telephone (215) 665-2013 - Facsimile Mark DeLuca Registration No. 33,229 PTO/SB/08b(08-03)
Approved for use through 07/31/2008. OMB 0651-0031
U.S. Patent and Tradamark Office: U.S. DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMENCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless contains a valid OMB control number
stude for form 1449B/PTO

Computer if Known

BARRY'S TRADE

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)
Sheet 1 of 1

NON PATENT LITERATURE DOCUMENTS

Examiner Cite Initials \* Include name of the author (in CAPITAL LETTERS) like of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue unumber(s), publisher, city and/or country where published.

Cohen, Mitchell B., "A Gradient in Expression Of The Escherichia Coli Heat-Stable Enterotoxin Receptor Exists Along The Villus-To-Crypt Axis Of Rat Small Intestine." Biochemical and Biophysical Research Communications, 1992;186 (1):483-490.

Examiner	Date	
Signature	 Considered	

"EXAMIRER: nitile if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered, include copy of this form with next communication to applicant.

'Applicant's unique citation designation number (optiona). 'Applicant is to place a check mark here if English language Translation is attached.

Applicative unique capacity designation funding (potonal). "Applicative as to paice a croscy make reper the pipels integrage Translation is attached.

New 1977 to process) an application. Confidentiality in governed by 35 U.S. (1,22 and 37 CFR 1.4. This collection to its estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application from to the USPTO. Time will vary depending upon the individual case. Any comment on the amount of time you require to complete this form and/or suggestions for deuting this process. The control of the complete the form and/or suggestions for deuting this process. Any comments on the amount of time you require to complete this form and/or suggestions for deuting this broaden, should be sent to the Chief form and the complete the form and/or suggestions for deuting this broaden, should be sent to the Chief form and the complete the form and/or suggestions for deuting this broaden, should be sent to the Chief form and the complete the form and/or suggestions for deuting this broaden, should be sent to the Chief form and the complete the form and or suggestion of reducing this broaden, should be sent to the Chief form and the complete the form and the suggestion of the chief form and the suggestion of the sugg

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.